Moderna News and Biotech Innovation Updates
Moderna Inc. (NASDAQ: MRNA) is a biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. Best known for its COVID-19 vaccine, Moderna leverages mRNA technology to develop treatments for infectious diseases, cancer, autoimmune conditions, and rare genetic disorders. Its modular platform enables rapid drug development and scalable manufacturing, positioning the company at the forefront of biotech innovation. Headquartered in Cambridge, Massachusetts, Moderna continues to expand its clinical pipeline and forge strategic partnerships with governments and research institutions worldwide. The company's long-term mission is to transform medicine by unlocking the potential of mRNA to treat and prevent a wide range of diseases.
245.81
4.44
1.84 %
At close
10/21
USD
Daily range
240.24
254.16
254.16
Weekly range
209.04
254.16
254.16
MRNA jumps over 4% after renewed institutional interest and bullish momentum
Moderna Inc (MRNA) surged 4.13% after its upcoming inclusion in the Nasdaq-100 index on October 9, 2026, drew renewed institutional and passive fund interest to the stock. The move is strongly ...
What's behind Moderna's latest 9.8% stock pullback?
Moderna Inc (MRNA) slumped 9.78% after opening with a significant downside gap, as enthusiasm surrounding the upcoming October 24 release of late-stage trial data for its mRNA cancer vaccine ...
Moderna stock resistance test at $197.74: Key levels to watch
Moderna (MRNA) stock is trading at $187.91 after a marginal increase for the session. The price remains below its key short-term and medium-term moving averages, but ...
MRNA slides around 6.5% as volatility contrasts with strong momentum signals
Moderna Inc (MRNA) dropped 6.45% today after sharp downside pressure encountered by the stock, even as recent bullish catalysts included its addition to the Nasdaq-100 Index and optimism around ...
Why is Moderna stock down 6.6% today?
Moderna Inc (MRNA) slumped 6.62% after multiple analysts downgraded the stock to Sell, raising concerns that its valuation has outpaced fundamentals even as the company reported positive results ...
Moderna rally accelerates before ESMO as traders watch for signs of exhaustion
Investors are once again pricing greater confidence in Moderna’s cancer vaccine program into the stock. From here, fresh developments could either extend the rally or give traders a reason to ...
What's behind Moderna's latest 8.0% stock surge?
Moderna Inc (MRNA) surged 8.02% after the FDA approved its XFG-adapted Spikevax and mNexspike COVID-19 vaccine formulas for the 2026-2027 season and positive Phase 3 results for its melanoma ...
Moderna remains overheated despite pullback as downside risk stays elevated
Moderna remains one of the most overheated biotech stocks after its powerful summer rally. The correction has already removed part of the extreme momentum, but the coming weeks could bring ...
Moderna stock price prediction: Range-bound trading expected
Moderna (MRNA) stock is trading at $145.55, down 2.23% for the session and hovering near the day’s low on elevated volatility. The price remains beneath its key ...
Moderna breaks higher as healthcare becomes market’s safe haven
Moderna stock partially played out the previous scenario, falling to $133.33 and stopping just short of the $131 target. A sharp reversal then followed, with MRNA recovering more than 15% from ...
MRNA climbs nearly 6% after upbeat Phase 3 melanoma vaccine results and strong technical momentum
Moderna Inc (MRNA) jumped 5.61% after its personalized mRNA melanoma vaccine, developed alongside Merck, achieved a positive Phase 3 clinical trial outcome. The rally is supported by a strong ...
Moderna shares drop more than 4% after upsized convertible debt announcement
Moderna Inc (MRNA) traded down 4.04% after announcing a $2.6 billion private placement of convertible senior notes due 2032, raising concerns about dilution and signaling caution among investors. ...
Moderna receives FDA approval for 2026-2027 vaccine formulas: Will MRNA hold $130.25 support?
Moderna said the U.S. Food and Drug Administration approved new 2026-2027 formulas of its Spikevax and mNEXSPIKE COVID-19 vaccines. The stock is down 3.9% on the day at $144.17.Moderna stated that ...
Moderna faces deeper pullback as convertible offering weighs on shares
Moderna is entering a profit-taking phase after its historic rally on positive Phase 3 results for its personalized cancer vaccine. A fresh plan to raise up to $2.3 billion through convertible ...
Moderna stock falls over 7% as heavy selling hits despite positive cancer vaccine data
Moderna Inc (MRNA) fell 7.17% after heavy intraday selling emerged, even as the company reported positive Phase 3 results for its personalized mRNA cancer vaccine. The scale of the decline ...
MRNA advances around 10.5% after Phase 3 trial success for mRNA cancer vaccine with Merck
Moderna Inc (MRNA) surged 10.59% after the company announced that its personalized mRNA cancer vaccine, in combination with Merck’s Keytruda, achieved both primary and key secondary endpoints in ...
Moderna stock drops more than 7% after positive melanoma vaccine results and FDA flu shot approval
Moderna Inc (MRNA) fell 7.32% today after a sharp downside gap, even as the company reported positive Phase 3 results for its personalized mRNA melanoma vaccine and received FDA approval for its ...
Moderna enters a wide consolidation phase after 177% surge
The market continues to digest the successful Phase 3 results for Moderna’s personalized melanoma therapy. Following the explosive rally, attention is gradually shifting from the trial ...
What's behind Moderna's latest 14.1% stock surge?
Moderna Inc (MRNA) surged 14.12% after unveiling a major Phase 3 clinical trial success for its personalized mRNA cancer vaccine in partnership with Merck. The magnitude of the move is supported ...
Why is Moderna stock down 22.2% today?
Moderna Inc (MRNA) plunged 22.28% after investors reacted with aggressive profit-taking to recent positive late-stage cancer vaccine results and new product approvals. The scale of the selloff ...
A second chance for Moderna: How a cancer vaccine sent shares soaring
Moderna shares surged after the success of its cancer vaccine. In a single day, the company added about $30 billion in market capitalization. But investors saw the news as having the potential ...
